| Active substance | elacestrant |
| Holder | Stemline Therapeutics Switzerland GmbH |
| Status | Running |
| Indication | Treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation, who have disease progression following one or two lines of endocrine therapy including a CDK 4/6 inhibitor. |
| Documents publics | Approbation |
| Information for the patient | |
| Informed consent | |
| last update | 11/10/2024 |